1 Catalyst That Could Cause SpaceX Stock to Drop. Should Investors Sell?

SpaceX stock is trading at $185, up 23% from its $150 IPO price, but the article warns that staggered lockup expirations could pressure shares over the next few months. Roughly 20% to 30% of stock may become available before the first earnings report, followed by another 7%, then 28% after second-quarter results, with the remainder unlocked 180 days post-IPO. The piece also flags a very rich 125 trailing price-to-sales ratio and suggests upcoming earnings reports could trigger volatility.

Analysis

The supply overhang is more important than the headline IPO pop. A staggered unlock creates a series of smaller but recurring sellable-float shocks, which tends to suppress implied scarcity and compress momentum multiples even if the business execution remains intact. That means the first tradeable effect is likely not a collapse, but a slower bleed in forward returns as marginal buyers wait for the unlock calendar to clear.

The real second-order risk is that early lockup windows coincide with the first public earnings prints, so the market is effectively forced to digest both insider selling capacity and fundamental truth serum at the same time. For a high-multiple private-market crossover name, even a merely “good not great” quarter can re-rate the stock lower because expectations are anchored to venture-style optionality, not public-market cadence. If the first report shows any slowdown in bookings, margins, or capex intensity, the downside can compound because lockup expiration gives every disappointed holder a convenient exit.

The contrarian read is that the lockup itself may be overhyped as a standalone catalyst; the bigger issue is duration mismatch between a long-duration story and a public-market float that now trades like a quasi-liquid momentum asset. If sentiment cools, the absence of broad mutual-fund sponsorship in the immediate post-IPO window can make price discovery asymmetric to the downside. Conversely, if the first earnings call validates a path to faster monetization, the stock could re-accelerate once the supply overhang clears, so timing matters more than direction.

For the named public comps, there is no direct fundamental read-through to NFLX or NVDA, but the setup reinforces a broader caution on premium-growth multiples and private-market-to-public-market transitions. NDAQ is the cleaner beneficiary on the other side of the trade: elevated post-IPO volatility and upcoming earnings scrutiny typically increase trading activity, data usage, and investor attention, even if that benefit is modest versus the valuation risk in the new issue itself.

Key Decisions for Investors

• Avoid initiating long exposure until after the first major lockup tranche and earnings print; the next 4-12 weeks are more likely to offer a better entry than chasing post-IPO momentum.
• If already long, consider a tactical hedge via short-dated put spreads 5-10% out of the money into the first earnings window; the payoff improves if the stock drifts lower on unlock-related supply rather than gaps sharply.
• Pair trade: short the new issue vs long NDAQ over the next 1-2 quarters to express a view that volatility/turnover rises while the issuer absorbs float overhang and multiple compression.
• For growth exposure, prefer NVDA/NFLX over the IPO name on a risk-adjusted basis; both have public-market operating histories and less event risk from insider supply release.
• Set a buy-wait trigger: only get constructive if the stock retraces 10-15% on unlock pressure but holds post-earnings support, which would signal the market has already digested the supply overhang.